RadNet, Inc.

RDNT • Medical - Diagnostics & Research

$73.71

▼ -0.91 (-1.22%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$5.80B

Growth

8.6%

Cash Flow

3/5

Trend

Mostly stable

Evidence

Positive free cash flow · 1.14Healthy liquidity · 1.76Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:08 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$73.71

Change-1.22%

Shares Out78.73M

Market Cap$5.80B

Enterprise Value$7.26B

52W Range50.82 - 85.84

Beta1.38

P/E-274.83

P/S2.56

P/B5.29

P/FCF-88.72

EV/Sales3.20

Price$73.71

Change-1.22%

Shares Out78.73M

Market Cap$5.80B

Enterprise Value$7.26B

52W Range50.82 - 85.84

Beta1.38

P/E-274.83

P/S2.56

P/B5.29

P/FCF-88.72

EV/Sales3.20

EV/EBITDA21.60

EV/FCF-110.99

Earnings Yield-0.36%

FCF Yield-1.13%

Dividend Yield0.00%

Gross Margin4.45%

Oper. Margin4.45%

Profit Margin-0.91%

Debt/Eq1.71

Current Ratio1.76

Quick Ratio1.76

Revenue 5Y8.63%

FCF 5Y2.37%

Target$65.00

Target Upside-11.82%

Target Median$65.00

Target Range65.00 - 65.00

Volume709.21K

Avg Volume852.74K

EPS Surprise-0.14

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

59/100

Growth Potential

Revenue and expansion

68/100

Price Attractiveness

Cheap or expensive today

47/100

Why this score▼

Positive free cash flow · 1.14Healthy liquidity · 1.76Weak profitability

Analyst view

Analyst sentiment and price target

RDNT

Analyst sentiment

Based on 11 analyst votes · 2026-09-04

91/100

Bullish

Hold

Bearish

Price Target

2026-08-12

Low

$65.00

Mean

$78.00

Median

$78.00

High

$91.00

Company Overview

IPO: 1/3/1997

Industry: Medical - Diagnostics & Research

P/B i: 5.29

Debt / Equity i: 1.71

Operating Margin: 4.45%

Net Margin: -0.91%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 1.71

Current Ratio: 1.76

Quick Ratio: 1.76

Status: Good

Insider Transactions

Recent executive and insider activity

SWARTZ DAVID L

Transaction: 06/18/2026

SELL

Change

-2,699

Price

$53.89

Filing

06/22/2026

Type

SELL

Berger Howard G

Transaction: 06/16/2026

SELL

Change

-90

Price

Not reported

Filing

06/18/2026

Type

SELL

Wesdorp Cornelis

Transaction: 06/16/2026

SELL

Change

-4,750

Price

$58.11

Filing

06/18/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
SWARTZ DAVID L	SELL	-2,699	$53.89	06/18/2026	06/22/2026
Berger Howard G	SELL	-90	Not reported	06/16/2026	06/18/2026
Wesdorp Cornelis	SELL	-4,750	$58.11	06/16/2026	06/18/2026
Forthuber Stephen M	SELL	-19,853	$58.61	06/15/2026	06/16/2026
Levitt Lawrence L	BUY	+2,946	Not reported	06/02/2026	06/03/2026
Jacobs Laura Pastre	BUY	+2,946	Not reported	06/02/2026	06/03/2026
SPURLOCK GREGORY E.	BUY	+2,946	Not reported	06/02/2026	06/03/2026
SWARTZ DAVID L	BUY	+2,946	Not reported	06/02/2026	06/03/2026
Berger Howard G	SELL	-25,992	$18.64	05/05/2026	05/06/2026
Berger Howard G	BUY	+25,992	$18.64	05/05/2026	05/06/2026
Sorensen Alma Gregory	SELL	-7,000	Not reported	03/19/2026	03/23/2026
Sorensen Alma Gregory	SELL	-800	$62.72	03/18/2026	03/18/2026
Sorensen Alma Gregory	SELL	-5,919	$61.72	03/16/2026	03/18/2026
Sorensen Alma Gregory	SELL	-16,831	Not reported	03/10/2026	03/12/2026
Sorensen Alma Gregory	BUY	+3,742	Not reported	03/10/2026	03/12/2026
Sorensen Alma Gregory	BUY	+16,533	Not reported	03/03/2026	03/05/2026
Murdock Michael N	BUY	+6,613	Not reported	03/03/2026	03/05/2026
Berger Howard G	BUY	+124,001	Not reported	03/03/2026	03/05/2026
HAMES NORMAN R	BUY	+3,100	Not reported	03/03/2026	03/05/2026
Forthuber Stephen M	BUY	+22,045	Not reported	03/03/2026	03/05/2026

About the Company

RadNet, Inc.

RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.

Source - link

Peers

BLCO BRKR BTSG CHE IRTC KRYS MMSI MTSR SHC TFX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Bamco Inc. NY Invests $77.77 Million in RadNet, Inc. $RDNT

Bamco Inc. NY acquired a new stake in RadNet, Inc. (NASDAQ: RDNT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,260,992 shares of the medical research company's stock, valued at approximately $77,765,000. Bamco Inc. NY owned about 1.60% of

Defense World

Head to Head Contrast: RadNet (NASDAQ:RDNT) and Oncology Institute (NASDAQ:TOI)

Oncology Institute (NASDAQ: TOI - Get Free Report) and RadNet (NASDAQ: RDNT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings

Defense World

RadNet: Imaging And AI Keep The Bull Case Intact

RDNT's advanced imaging mix is expanding. I think this will continue to support its improving revenue quality and margins. RDNT's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. DeepHealth is RDNT's second growth leg, as it pairs external software sales with internal workflow efficiencies.

Seeking Alpha

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

Zacks Investment Research

RadNet (NASDAQ:RDNT) Trading Up 6.9% on Earnings Beat

RadNet, Inc. (NASDAQ: RDNT - Get Free Report)'s stock price rose 6.9% during trading on Monday following a stronger than expected earnings report. The stock traded as high as $74.41 and last traded at $77.4050. Approximately 156,969 shares traded hands during trading, a decline of 81% from the average session volume of 830,771 shares. The stock

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-11	-0.14	-0.28	-0.14
2026-03-02	0.19	0.23	0.04
2025-11-09	0.2229	0.2	-0.0229
2025-08-10	0.17	0.31	0.14
2025-05-11	-0.17	-0.35	-0.18
2025-02-27	0.21	0.22	0.01
2024-11-10	0.1358	0.18	0.0442
2024-08-07	0.16	0.16	0
2024-05-08	-0.09	0.07	0.16
2024-02-29	0.11	0.2	0.09
2023-11-08	0.06	0.14	0.08
2023-08-08	0.07	0.24	0.17